Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $5.5M
- Enterprise value
- $5.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.70
- 52-wk low
- $0.19
- Beta
- —
- Shares out
- 1.4M
5-year trend
What this company does
ITEM 1. Business Overview and Recent Developments We are a holding company incorporated in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company’s primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor technology and…
AI summary unavailable — showing raw filing excerpt
Generated from ADVB's filing dated 2025-10-08
Key risks
ITEM 1A. Risk Factors Investing in our securities involves a high degree of risk. Before making any investment decision, you should consider carefully the following risks and other information in this Report, including our consolidated financial statements and related notes. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties that we are unaware of or that we believe are not material at the time could also materially adversely affect our business, financial condition or results of operations. In any case, the value of our Common Stock could decline, and you could lose all or part of your investment. Please also see the section entitled…
AI summary unavailable — showing raw filing excerpt
Generated from ADVB's filing dated 2025-10-08
Profitability
Return on equity
-93.7%
44.0%Return on assets
-50.0%
19.8%Leverage
Debt / equity
0.87×
48.1%Debt / assets
46.6%
25.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $6.5M | +812.7% | — |
Q3 2025 2025-09-30 | — | — | $-386.9K | -45.7% | — |
Q2 2025 2025-06-30 | — | — | $-701.6K | — | — |
Q1 2025 2025-03-31 | — | — | $-1.4M | -31.0% | — |
Q4 2024 2024-12-31 | — | — | $-907.9K | -524.7% | — |
Q3 2024 2024-09-30 | — | — | $-265.6K | — | — |
Q1 2024 2024-03-31 | — | — | $-1.1M | — | — |
Q4 2023 2023-12-31 | — | — | $-145.3K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on ADVB — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ADVB in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ADVB
Institutional value
$9.2K
Total shares held
44.1K
Distinct holders
3
-2 vs prior
As of
2025-12-31
Prior: 2025-09-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | XTX Topco Ltd | 27.3K | $8.0K | -25.0K (-47.8%) | Trimmed |
| 2 | UBS Group AG | 4.3K | $1.3K | +965 (+28.7%) | Added |
| 3 | Virtu Financial LLC | 12.6K | $4 | -19.5K (-60.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ADVB's latest filing finishes processing.